Drug Shortage Report for SANDOSTATIN LAR
| Report ID | 254019 |
| Drug Identification Number | 02239324 |
| Brand name | SANDOSTATIN LAR |
| Common or Proper name | SANDOSTATIN LAR 20MG |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | OCTREOTIDE |
| Strength(s) | 20MG |
| Dosage form(s) | POWDER FOR SUSPENSION, SUSTAINED-RELEASE |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | 1 x 20 MG SYRINGE |
| ATC code | H01CB |
| ATC description | HYPOTHALAMIC HORMONES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2025-04-14 |
| Actual start date | |
| Estimated end date | 2025-06-17 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-04-15 |
| Company comments | Product on allocation |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
| Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2025-04-15 | English | Compare |
| v5 | 2025-04-03 | French | Compare |
| v4 | 2025-04-03 | English | Compare |
| v3 | 2025-04-03 | French | Compare |
| v2 | 2025-04-03 | French | Compare |
| v1 | 2025-04-03 | English | Compare |
Showing 1 to 6 of 6